EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Precision mRNA Delivery via Ultrasound‐Controlled Release Perfluorocarbon Emulsions: An Innovative Ultrasound Theranostic Strategy with 19 F MRI Feasibility

Haikun Liu, Mark Louis P Vidallon, Yuyang Song, Aidan P G Walsh, Henry Gordon, Shulei Ren, Pengkai Shi, Bangyan Xu, Mitchell J Moon, Sylvain Trépout, Rico F Tabor, Alexis I Bishop und 3 weitere

Small · 2026

DOI: 10.1002/smll.202506806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2026. Verfasst von Haikun Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia. Hauptthemen laut MEDLINE: Fluorocarbons, RNA, Messenger, Theranostic Nanomedicine, Fluorine-19 Magnetic Resonance Imaging. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, mRNA Victoria, Weary Dunlop Foundation Medical Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) therapeutics provide promising opportunities in cardiovascular diseases. However, effective vascular mRNA delivery requires precise delivery, controlled release, and efficient transfection. To address these challenges, the study utilizes phase‐change perfluorocarbon nanodroplets (PFC NDs) as a unique theranostic platform, integrating multimodal imaging with ultrasound‐triggered mRNA release for enhanced vascular transfection. Lipid‐coated PFC NDs are engineered using perfluoro‐crown‐ether (PFCE), perfluorohexane (PFH), and perfluoropentane (PFP) as core materials. These nanodroplets (200–300 nm) are optimized for mRNA loading and cellular uptake, exhibiting strong ultrasound contrast in tissue‐mimicking phantoms and in vivo. Each PFC generated distinct fluorine‐19 magnetic resonance imaging signals, allowing tri‐spectral imaging capabilities. In vitro, PFH and PFP NDs increased enhanced green fluorescent protein mRNA transfection in CHO cells ( p < 0.0001), with ultrasound stimulation further improving efficiency compared to unstimulated controls ( p < 0.05). In vivo ultrasound‐guided activation of PFH NDs resulted in higher mCherry protein expression in murine carotid arteries ( p < 0.05), demonstrating site‐specific gene therapy. This study establishes PFH NDs as an advanced theranostic platform for vascular mRNA delivery, integrating diagnostics and therapeutics into a single system. By leveraging ultrasound‐responsive activation, these nanodroplets overcome existing delivery limitations, offering a new avenue for precision medicine in cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluorocarbonsRNA, MessengerTheranostic NanomedicineFluorine-19 Magnetic Resonance ImagingMagnetic Resonance ImagingAnimalsEmulsionsMiceCHO CellsNanoparticlesCricetulusFeasibility StudiesTransfectionUltrasonography

Stichwörter der Autor:innen

mRNAmagnetic resonance imagingperfluorocarbon nanodropletstheranosticultrasound

Substanzen

FluorocarbonsEmulsionsRNA, Messenger

Autor:innen und Institutionen

  • Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.
  • Centre for Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.
  • Department of Cardiometabolic Health, University of Melbourne, Parkville, VIC, 3010, Australia.
  • School of Chemistry, Monash University, Clayton, VIC, 3800, Australia.
  • Baker Department of Cardiovascular Research, Translation and Implementation La Trobe University, Bundoora, VIC, 3086, Australia.
  • Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.

ORCID-Profile: Xiaowei Wang

Förderung

  • National Health and Medical Research Council
  • mRNA Victoria
  • Weary Dunlop Foundation Medical Research Grant
  • German Research Foundation
  • NHMRC L3 Investigator Fellowship
  • Baker Heart and Diabetes Institute
  • National Heart Foundation of Australia
  • Australian Institute of Nuclear Science and Engineering

Zitieren

APA

Liu, H., Vidallon, M. L. P., Song, Y., Walsh, A. P. G., Gordon, H., Ren, S., Shi, P., Xu, B., Moon, M. J., Trépout, S., Tabor, R. F., Bishop, A. I., Flögel, U., Peter, K., & Wang, X. (2026). Precision mRNA Delivery via Ultrasound‐Controlled Release Perfluorocarbon Emulsions: An Innovative Ultrasound Theranostic Strategy with 19 F MRI Feasibility. Small. https://doi.org/10.1002/smll.202506806

Vancouver

Liu H, Vidallon MLP, Song Y, Walsh APG, Gordon H, Ren S, et al. Precision mRNA Delivery via Ultrasound‐Controlled Release Perfluorocarbon Emulsions: An Innovative Ultrasound Theranostic Strategy with 19 F MRI Feasibility. Small. 2026. doi:10.1002/smll.202506806

BibTeX
@article{Liu2026,
  author = {Liu, Haikun and Vidallon, Mark Louis P and Song, Yuyang and Walsh, Aidan P G and Gordon, Henry and Ren, Shulei and Shi, Pengkai and Xu, Bangyan and Moon, Mitchell J and Trépout, Sylvain and Tabor, Rico F and Bishop, Alexis I and Flögel, Ulrich and Peter, Karlheinz and Wang, Xiaowei},
  title = {Precision mRNA Delivery via Ultrasound‐Controlled Release Perfluorocarbon Emulsions: An Innovative Ultrasound Theranostic Strategy with 19 F MRI Feasibility},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.202506806}
}
Kostenlos starten →